

High-sensitive cardiac troponin T as a marker of hemorrhagic complications in elderly patients anticoagulated for non-massive pulmonary embolism.

Aurélien Simona¹, Andreas Limacher², Marie Méan³, Olivier Golaz⁴, Henri Bounameaux⁵,
Drahomir Aujesky⁶, Marc Righini⁵, Nicolas Vuilleumier⁴

¹ Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

² CTU Bern and Department of Clinical Research, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.

³ Division of Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland.

⁴ Division on Laboratory Medicine, Diagnostics Department and Department of Internal Medicine Specialities, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland.

⁵ Division of Angiology and Haemostasis, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland.

⁶ Division of General Internal Medicine, Bern University Hospital and University of Bern, Switzerland.

Corresponding author

Aurélien Simona

Geneva University Hospitals, rue Gabrielle-Perret-Gentil 4, 1205 Genève

Division of Clinical Pharmacology and Toxicology

email: aurelien.simona@hcuge.ch

phone: +41223729932

1 **Abstract**

2 **Background:** Recent data have raised concerns about the risk/benefit ratio of thrombolysis in
3 non-high risk pulmonary embolism patients due to increased serious bleeding events. Whether
4 cardiac biomarkers could be of help for bleeding risk stratification in this setting remains
5 elusive.

6 **Objectives:** To determine the prognostic accuracy of hs-cTnT, NT-proBNP, RIETE and PESI
7 score for the occurrence of clinically relevant bleeding (CRB) in elderly patients under
8 conventional anticoagulation therapy for non-massive pulmonary embolism (NMPE).

9 **Methods:** We evaluated 230 elderly patients with available blood sample taken within one
10 day from diagnosis. The primary study endpoint was CRB at 1, 3 and 24 months. Prognostic
11 accuracies and associations were determined using C-statistics and subhazard ratios (SHR),
12 respectively.

13 **Results:** hs-cTnT displayed the highest discriminatory power at 1 month (C-statistics: 0.77,
14 95% CI: 0.68–0.88) which remained stable over time. Although C-statistics comparison
15 indicated that hs-cTnT was not statistically superior to RIETE score (0.77 vs 0.67, $p=0.11$),
16 adding hs-cTnT to RIETE score significantly improved the C-statistics from 0.67 to 0.78
17 ($p=0.02$). SHRs indicated that for each hs-cTnT log-unit increase, there was a 58% increase in
18 the risk of CRB independently of the RIETE score (adjusted SHR: 1.58, 95% CI: 1.31-1.92).
19 At the pre-specified cut-off of 14 ng/l, the negative predictive value of hs-cTnT was 96.9%
20 (95% CI: 91.4-99.0) and 94.9 (95%CI: 88.6-97.8) at 1 and 3 months, respectively.

21 **Conclusion:** In elderly, hs-cTnT provides incremental prognostic information over the RIETE
22 score and could represent a valuable tool to identify NMPE patients at low risk of bleeding.

23

24 **Keywords:** Natriuretic Peptide, Brain ; Troponin T ; Pulmonary Embolism ; Hemorrhage ;
25 RIETE score

26

1 **Abbreviations list**

- 2 CRB : clinically relevant bleeding
- 3 NMPE : non-massive pulmonary embolism
- 4 PE : pulmonary embolism
- 5 SHR : subhazard ratios
- 6
- 7

1 **Introduction**

2 Risk stratification in hemodynamically stable patients with pulmonary embolism (PE) has
3 gained considerable interest as being susceptible to discriminate between non-massive PE
4 patients at low-risk or those at intermediate risk of complications, which could respectively be
5 either eligible for an outpatient treatment or susceptible to benefit from thrombolysis on top of
6 conventional anticoagulation therapy (1–4). Currently, the identification of low-risk patients
7 mostly rely on the pulmonary embolism severity index (PESI) score known to be effective in
8 safely identifying such patients that could possibly be treated in an ambulatory fashion
9 (1,4,5). Cardiac biomarkers, such as B-type natriuretic peptides (BNP and NT-proBNP) and
10 cardiac troponin have also shown an interesting potential for rule-out purposes given their
11 negative predictive values above 95% in predicting PE-related complications (6–12), and their
12 ability to provide incremental prognostic information to PESI score in elderly patients (11).
13 On the other hand, the optimal identification and management of intermediate risk patient is
14 still unclear. Knowing whether radiological or biochemical features of right ventricular
15 dysfunction/dilatation should be used for such purpose is still elusive. Furthermore, current
16 evidences provided by the Pulmonary Embolism Thrombolysis (PEITHO) randomized-
17 controlled study do not support the need of a more aggressive management by fibrinolysis to
18 improve short or long term outcomes of such patients (13,14). If those results can be
19 interpreted as the absence of thrombolysis benefit in PE patients at intermediate risk, they
20 may also emphasize the need of a prompt and accurate major bleeding risk assessment before
21 fibrinolytic therapy administration.

22 Because several cardiac biomarkers-oriented clinical trials in PE used composite endpoints
23 including the occurrence of bleeding complications (6,7,9–11), and because natriuretic
24 peptides and troponins have been respectively shown to act *in vitro* and *in vivo* as
25 anticoagulant (15–17) and anti-angiogenic factors (18–21), we hypothesized that high-

1 sensitive cardiac troponin T (hs-cTnT) and NT-proBNP levels upon admission could also
2 reflect the global endothelial integrity of the vascular bed, and thereby could predict the
3 patient propensity of bleeding while under anticoagulation therapy. Therefore, we challenged
4 the prognostic accuracies of hs-cTnT and NT-proBNP, alone and in combination, to predict
5 hemorrhagic complications prediction, and compared them to the RIETE score which is
6 dedicated to assess the hemorrhagic risk in PE patients under anticoagulation (22,23).

7

8 **Methods**

9 **Patient population and study design**

10 The present study is an ancillary study of a swiss prospective cohort study (SWITCO65+)
11 which involved university as well as high-volume non-university hospitals. SWITCO65+
12 aimed at assessing long-term outcomes of patients aged 65 or older with a diagnosis of deep
13 vein thrombosis (DVT) or PE (5,11,12). The study protocol was approved by the research
14 ethics committee of each institution, and all patients provided written informed consent.

15 A total of 695 patients with acute PE diagnosed from September 2009 to March 2012 were
16 considered for this study. PE diagnosis was retained after documentation of a DVT with
17 compression ultrasonography or angiography or when diagnostic imaging were either positive
18 for PE (pulmonary angiography or spiral CT) or indicated PE with a high probability
19 (ventilation perfusion scintigraphy) (5,11,12). Briefly, exclusion criteria included thrombosis
20 at a site other than lower extremity or thrombosis related to catheter insertion, inadequate
21 fluency in German or French, conditions making follow-up unlikely (i.e. terminal illness) or
22 informed consent unavailable (i.e. severe dementia) and previous enrolment in the cohort.

23 For the present study, 10 patients with massive PE as defined with a systolic blood pressure \leq
24 90 mmHg (1), as well as 8 patients not allowing use of their personal data or withdrawing

1 consent within one day from inclusion, and 450 patients for which blood samples were
2 obtained later than one day after diagnosis were excluded. In total, 230 patients were available
3 for the analysis. Baseline demographic characteristics, clinical data and clinical scores (PESI
4 (24) and RIETE scores) were prospectively collected by medical records review performed by
5 trained research nurses.

6 **Patients' follow-up**

7 Follow-up was obtained for all patients at 1, 3 and 24 months months after enrolment. Patients
8 as well as physicians in charge were told to refer to the investigators whenever recurrent
9 respiratory or lower extremity symptoms occurred. Telephone interviews and face-to-face
10 evaluations of all patients were organized at the end of the follow-up period by study
11 coordinators who remained blinded to the results of analyses (25). All health-related events
12 were reported by patients after hospital discharge (readmission to the hospital, any medical
13 appointment, treatment modification, medical investigation and/or hemorrhagic
14 complication). Review of medical files and contact with the family doctor were performed in
15 case of suspected clinical event.

16 **Definition of endpoints**

17 The predetermined primary endpoint of this study consisted in clinically relevant bleedings
18 (i.e. combination of clinically relevant non-major bleeding as well as major bleeding).

19 Clinically relevant nonmajor bleeding episode was defined as bleeding not meeting the
20 definition of major bleeding, but requiring physician consultation or evaluation in the
21 emergency department (26).

22 The secondary endpoint consisted in major bleeding defined as: i) fatal bleeding, and/or ii)
23 symptomatic bleeding at a critical site (intracranial, intraspinal, intraocular, retroperitoneal,
24 intra-articular, pericardial or intramuscular with compartment syndrome), and/or iii) overt

1 bleeding with a reduction in haemoglobin levels of ≥ 20 g/L or leading to transfusion of at
2 least two units of packed red blood cells (27).

3 Primary and secondary endpoints were adjudicated upon the consensus of a committee that
4 was blinded to biochemical results.

5 **Sample Collection**

6 Blood collection and sample processing details were described elsewhere (28).

7 **Biochemical Analyses**

8 Blood samples were analysed to the University Hospitals of Geneva so as to minimize
9 analytical bias. NT-proBNP and hs-cTnT were measured by electrochemiluminescence
10 methods on routine autoanalysers (Elecsys™, Roche, Switzerland). We used a cut-off of 14
11 ng/l for hs-cTnT and 300 pg/ml for NT-proBNP. Details for justification of these cut-offs
12 were described elsewhere (7,11,12,28,29).

13 **RIETE score assessment**

14 The RIETE score allows the determination of major bleeding risk in patients undergoing
15 anticoagulation treatment for pulmonary embolism (22,23). This score is computed for each
16 patient according to the presence of six clinical features, including anamnesis of recent
17 bleeding (< 2 weeks), creatinine value above 106 $\mu\text{mol/L}$, presence of anemia (Hb <12 g/dL
18 for women, Hb <13 g/dL for men), presence of malignancy, clinically overt PE, and age >75
19 years old (22,23). As shown in Table 1, each of these items has a specific weighting which is
20 summed together to generate a total score with the following risk classes: 0 = low risk, 1-4 =
21 intermediate risk, above 4 = high risk (22,23).

22 **Table 1. RIETE bleeding risk score and risk classes**

<i>Items</i>	<i>Points</i>
Recent major bleeding	2
Creatinine levels >109 $\mu\text{mol/l}$	1.5

Anemia	1.5
Cancer	1
Clinically overt PE	1
Age >75 years	1

<i>Incident risk of major bleeding per risk class</i>	<i>Corresponding cumulated points</i>
Low risk: 0.3% (95% CI: 0.1-0.6%)	0
Intermediate Risk: 2.6% (95% CI: 2.3-2.6%)	1-4
High risk: 7.3% (95% CI: 5.6-9.3%)	> 4

Adapted from (22,23)

1

2 **Statistical analysis**

3 A Chi-squared test or a non-parametric Wilcoxon rank-sum test were used as appropriate to
4 compare patients baseline characteristics with and without clinically relevant bleeding. The
5 Kaplan-Meier technique and the log-rank test were used to estimate and compare the
6 cumulative incidence of outcomes for categories of biomarker levels. For hs-cTNT and NT-
7 proBNP, we used the prospectively defined and validated cut-offs of 14 ng/l and 300 pg/ml,
8 respectively (11,12). The discriminative ability of the biomarker levels and the clinical scores
9 for events up to 1, 3 and 24 months was assessed by Harrell's C concordance statistics, which
10 is equivalent to the area under the ROC curve (AUC) in the case of binary outcomes.
11 Associations of biomarker levels and clinical scores with outcomes were assessed using
12 competing-risk regression accounting for non-bleeding-related death as a competing event,
13 according to the method of Fine and Gray (29). Results are reported as unadjusted and
14 adjusted subhazard ratios (SHR) with corresponding 95% CIs and p-values. SHR are adjusted
15 for the RIETE score (22,23) and periods of anticoagulation during follow-up as a time-
16 varying covariate for both endpoints. The RIETE score was only adjusted for anticoagulation.
17 Missing values in score items were assumed to be normal. All analyses were done using Stata
18 15 (Stata Corporation, College Station, Texas, USA).

19 **Results**

1 Patients' baseline characteristics

2 Patients' demographic characteristics and median biomarker values upon admission are listed
 3 in Table 2. At inclusion, patients with clinical relevant bleeding during follow-up tended to be
 4 older, were more likely to display an altered mental status, to be diabetic, known for
 5 cerebrovascular events, and to have been immobilized during the last three months (Table 2).
 6 Of note, hs-cTnT as well as the RIETE score upon inclusion were significantly higher in
 7 patients that had a clinically relevant bleeding episode than those who did not during follow-
 8 up. There were no other significant differences between these two groups of patients (Table
 9 2).

10 **Table 2. Patients baseline characteristics**

	All	With CR Bleeding Event	Without CR Bleeding Event	p-value
	% (n) or median (IQR)	% (n) or median (IQR)	% (n) or median (IQR)	
total N	230	64	166	
Age	75 (69-82)	77.0 (70.3-83.0)	74.0 (69.0-81.0)	0.050
Female gender	94 (41%)	25 (39%)	69 (42%)	0.729
DVT (all)	47 (20%)	12 (19%)	35 (21%)	0.694
Proximal DVT (versus distal)	41 (18%)	10 (16%)	31 (19%)	0.588
Systolic BP <100 mmHg	4 (2%)	0 (0%)	4 (2%)	0.210
Heart rate ≥110 beats/min	27 (12%)	4 (6%)	23 (14%)	0.108
Respiratory rate ≥30/min	9 (4%)	2 (3%)	7 (4%)	0.649
Oxygen saturation <90%	23 (10%)	3 (5%)	20 (12%)	0.062
Temperature <36°C	18 (8%)	4 (6%)	14 (8%)	0.577
Body mass index (kg/m ²)	26.6 (23.9-29.8)	26.6 (23.0-29.6)	26.6 (24.2-29.9)	0.609
Altered mental status	6 (3%)	4 (6%)	2 (1%)	0.031
Diabetes mellitus	35 (15%)	14 (22%)	21 (13%)	0.081
Coronary heart disease	41 (18%)	13 (20%)	28 (17%)	0.541
Heart failure†	23 (10%)	9 (14%)	14 (8%)	0.202
Arterial hypertension	150 (65%)	40 (63%)	110 (66%)	0.591
Chronic renal disease††	39 (17%)	12 (19%)	27 (16%)	0.653
Chronic lung disease¶	33 (14%)	11 (17%)	22 (13%)	0.446
Cerebrovascular disease‡	20 (9%)	9 (14%)	11 (7%)	0.073
Smoker (current or past)	116 (50%)	27 (42%)	89 (54%)	0.146
Current oestrogen therapy	5 (2%)	1 (2%)	4 (2%)	0.689

during the last 3 months

Major surgery during the last 3 months	33 (14%)	10 (16%)	23 (14%)	0.732
Immobilization during the last 3 months§	52 (23%)	20 (31%)	32 (19%)	0.052
Prior VTE	70 (30%)	21 (33%)	49 (30%)	0.627
Prior DVT	42 (18%)	13 (20%)	29 (17%)	0.617
Active cancer#	39 (17%)	10 (16%)	29 (17%)	0.738
Concomitant antiplatelet therapy	63 (33%)	20 (37%)	43 (31%)	0.496
hs-cTnT (ng/l)	16.6 (8.2-33.9)	27.5 (12.5-47.2)	14.6 (6.8-28.7)	<0.001
hs -cTnT > 14 pg/ml	132 (57%)	46 (72%)	86 (52%)	0.006
NT-proBNP (pg/ml)	634.2 (227.2-2191.8)	957.0 (334.1-2286.3)	554.7 (186.4-2134.5)	0.187
NT-proBNP > 300 pg/ml	157 (68%)	49 (77%)	108 (65%)	0.093
PESI score	94.0 (80.0-110.3)	91.5 (79.3-114.0)	95.0 (80.0-109.0)	0.794
PESI > 85	150 (65%)	41 (64%)	109 (66%)	0.819
RIETE score	2.0 (2.0-3.5)	2.5 (2.0-3.9)	2.0 (1.0-3.5)	0.029
RIETE > 4	31 (13%)	13 (20%)	18 (11%)	0.059
Ratio RVEDD¶/LVEDD** > 0.9	60 (26%)	19 (30%)	41 (25%)	0.730

Data were missing for ratio RVEDD/LVEDD > 0.9 (20%), respiratory rate (17%), oxygen (7%), temperature (2%), estrogen therapy (0.4%), smoking status (0.4%), and BMI (0.4%).

†Acute heart failure NYHA class II/IV during the last 3 months, left or right heart failure, known left ventricular ejection fraction of <40%, known history of systolic or diastolic heart failure, or forward or backward heart failure.

††Chronic glomerulonephritis, cystic kidney disease, diabetic or hypertensive nephropathy, myeloma-related nephropathy, or chronic interstitial nephritis.

¶Chronic obstructive pulmonary disease, bronchiectasies, cystic fibrosis, lung fibrosis, or active asthma.

‡Transient ischemic attack or history of ischemic or hemorrhagic stroke.

§Fracture or cast of the lower extremity, voyage in sitting position for >6 hours during the last 3 months, or bed rest >72 hours.

#Cancer (solid or hematologic) requiring surgery, palliative care during the last 3 months, radiotherapy, or chemotherapy.

¶¶RVEDD: right ventricular end-diastolic diameter

‡‡LVEDD: left ventricular end-diastolic diameter

Abbreviations:

DVT: deep venous thrombosis

Incidence of endpoints according to different follow-up period

Clinically relevant bleeding was observed in 8.8% (20/230) of patients up to 1 month, 12.3% (28/230) up to 3 months and 29.1% (64/230) up to 24 months.

Major bleeding was seen in 6.2% (14/230) of patients up to 1 month, 7.0% (16/230) up to 3 months and 14.1% (31/230) up to 24 months (Table S1 - supplementary data).

1

2 **Associations of cardiac biomarkers, PESI and RIETE score with** 3 **study endpoints**

4 As shown in Table 3 and Fig. 1, with the exception of the PESI score that showed no
5 discrimination at any time during follow-up, both cardiac biomarkers and the RIETE score
6 displayed a significant discriminative power for clinically relevant bleeding. hs-cTnT had the
7 highest prognostic accuracy for the occurrence of clinically relevant bleeding at one month
8 but was not statistically superior to the RIETE score (respective C-statistics: 0.77 vs 0.67,
9 $p=0.118$). When hs-cTnT was added to the RIETE score, the C-statistics increased
10 significantly from 0.67 (95% CI: 0.55-0.79) to 0.78 (95% CI: 0.67-0.82, $p=0.023$). On the
11 other hand, adding the RIETE score to hs-cTnT did not substantially increase the C-statistics
12 (0.77 to 0.78, $p=0.782$). Similar trends were observed with major bleeding (Table 4).

13 **Table 3. C-statistics evolution and comparison for biomarkers, RIETE and PESI score**
14 **for clinically relevant bleeding**

	C-statistics* (95% CI)	p-value
1 month		
hs-cTnT (ng/l)	0.77 (0.66-0.88)	
NT-proBNP (pg/ml)	0.63 (0.52-0.74)	
PESI score	0.50 (0.36-0.64)	
RIETE score	0.67 (0.55-0.79)	
hs-cTnT (ng/l) added to RIETE score	0.78 (0.67-0.89)	0.023
RIETE score added to hs-cTnT (ng/l)	0.78 (0.67-0.89)	0.782
<u>C-statistics comparison</u>		
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)		0.009
hs-cTnT (ng/ml) vs RIETE score		0.118
NT-proBNP (pg/ml) vs RIETE score		0.424
3 months		
hs-cTnT (ng/l)	0.75 (0.66-0.84)	
NT-proBNP (pg/ml)	0.63 (0.53-0.72)	
PESI score	0.51 (0.40-0.63)	
RIETE score	0.66 (0.55-0.76)	
hs-cTnT (ng/l) added to RIETE score	0.75 (0.65-0.84)	0.017

RIETE score added to hs-cTnT (ng/l) 0.75 (0.65-0.84) 0.923

C-statistics comparison

hs-cTnT (ng/l) vs NT-proBNP (pg/ml) 0.013

hs-cTnT (ng/ml) vs RIETE score 0.085

NT-proBNP (pg/ml) vs RIETE score 0.550

24 months

hs-cTnT (ng/l) 0.67 (0.61-0.74)

NT-proBNP (pg/ml) 0.58 (0.52-0.65)

PESI score 0.53 (0.46-0.61)

RIETE score 0.61 (0.54-0.68)

hs-cTnT (ng/l) added to RIETE score 0.67 (0.60-0.74) 0.034

RIETE score added to hs-cTnT (ng/l) 0.67 (0.60-0.74) 0.667

C-statistics comparison

hs-cTnT (ng/l) vs NT-proBNP (pg/ml) 0.005

hs-cTnT (ng/ml) vs RIETE score 0.104

NT-proBNP (pg/ml) vs RIETE score 0.510

1 *all variables are used continuous

2 **Table 4. C-statistics evolution and comparison for biomarkers, RIETE and PESI score**
 3 **for major bleeding**

	C-statistics* (95% CI)	p-value
1 month		
hs-cTnT (ng/l)	0.73 (0.59-0.88)	
NT-proBNP (pg/ml)	0.63 (0.51-0.76)	
PESI score	0.49 (0.35-0.64)	
RIETE score	0.68 (0.54-0.82)	
hs-cTnT (ng/l) added to RIETE score	0.74 (0.60-0.88)	0.069
RIETE score added to hs-cTnT (ng/l)	0.74 (0.60-0.88)	0.870
<u>C-statistics comparison</u>		
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)		0.045
hs-cTnT (ng/ml) vs RIETE score		0.441
NT-proBNP (pg/ml) vs RIETE score		0.527
3 months		
hs-cTnT (ng/l)	0.75 (0.62-0.88)	
NT-proBNP (pg/ml)	0.67 (0.55-0.78)	
PESI score	0.55 (0.40-0.69)	
RIETE score	0.70 (0.57-0.83)	
hs-cTnT (ng/l) added to RIETE score	0.76 (0.63-0.88)	0.043
RIETE score added to hs-cTnT (ng/l)	0.76 (0.63-0.88)	0.925
<u>C-statistics comparison</u>		
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)		0.054
hs-cTnT (ng/ml) vs RIETE score		0.418
NT-proBNP (pg/ml) vs RIETE score		0.578
24 months		
hs-cTnT (ng/l)	0.65 (0.54-0.75)	

NT-proBNP (pg/ml)	0.62 (0.53-0.71)	
PESI score	0.53 (0.43-0.63)	
RIETE score	0.66 (0.56-0.76)	
hs-cTnT (ng/l) added to RIETE score	0.67 (0.57-0.77)	0.461
RIETE score added to hs-cTnT (ng/l)	0.67 (0.57-0.77)	0.555
<u>C-statistics comparison</u>		
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)		0.497
hs-cTnT (ng/ml) vs RIETE score		0.840
NT-proBNP (pg/ml) vs RIETE score		0.457


1 *all variables are used continuous

2

3 On the other hand, the prognostic accuracy of NT-proBNP was substantially lower for the
 4 primary endpoint with C-statistics value of 0.63 (95% CI: 0.52 – 0.74), 0.63 (95% CI: 0.53 –
 5 0.72) and 0.58 (95% CI: 0.52 – 0.65) at 1, 3, and 24 months, respectively. The PESI score did
 6 not predict the primary outcome with significant accuracy at any time of the follow-up (Table
 7 3 and Fig. 1).

8

9 **Fig 1. ROC curve analysis for clinically relevant bleeding at 1 month.** ROC curves for hs-
 10 cTnT, NT-proBNP, RIETE and PESI score are shown.



11

12

13 Corroborating these results, competing-risks regression analyses indicated that values of hs-
 14 cTnT above 14 ng/l were significantly associated with clinically relevant bleeding at 24
 15 months before (SHR 2.25, 95% CI: 1.32 – 3.86) and after (SHR 1.87, 95% CI: 1.05 – 3.34)

1 adjustment for the RIETE score (Table 5). When used as a continuous variable, hs-cTnT was
 2 significantly associated with clinically relevant bleeding over the 24 months follow-up period
 3 after adjustment for RIETE score with SHR (95% CI) ranging from 1.58 (1.31 – 1.92) up to 1
 4 month to 1.31 (1.10 – 1.55) up to 24 months per log-unit increase. Regarding NT-proBNP
 5 values above 300 pg/ml, significant associations with the primary endpoint were observed up
 6 to 3 months (SHR: 4.09, 95% CI: 1.23 – 13.59) and 24 months (SHR: 1.77, 95% CI: 1.01 –
 7 3.10) before adjustment. However, after adjustment, associations were not significant
 8 anymore. Unlike hs-cTnT, NT-proBNP was not significantly associated with clinically
 9 relevant bleeding at any time after adjustment for RIETE score when used as a continuous
 10 variable. PESI score was not associated with the primary endpoint at any time while RIETE
 11 score showed an increased SHR ranging between 1.58 (95% CI: 1.16 – 2.16) up to 1 month
 12 and 1.30 (95% CI: 1.07 – 1.57) up to 24 months (Table 5). Analysis results for major bleeding
 13 showed similar trends (Table S2 - supplementary data).

14 **Table 5. Association of biomarkers, PESI and RIETE score with clinically relevant**
 15 **bleeding.**


	Crude SHR (95% CI)	p-value	Adjusted SHR* (95% CI)	p-value
1 month				
hs-cTnT >14ng/l	4.43 (1.30 - 15.07)	0.017	3.16 (0.86 - 11.68)	0.084
hs-cTnT (ng/l) ¹	1.59 (1.31 - 1.93)	<0.001	1.58 (1.31 - 1.92)	<0.001
NT-proBNP >300pg/ml	4.30 (0.99 - 18.69)	0.052	3.00 (0.74 - 12.14)	0.124
NT-proBNP (pg/ml) ¹	1.23 (0.95 - 1.60)	0.120	1.06 (0.81 - 1.39)	0.676
PESI score ²	0.99 (0.81 - 1.20)	0.900	0.83 (0.63 - 1.09)	0.182
RIETE score ³	1.58 (1.16 - 2.16)	0.004	1.60 (1.17 - 2.19)	0.004
3 months				
hs-cTnT >14ng/l	3.70 (1.42 - 9.64)	0.008	2.68 (0.99 - 7.26)	0.053
hs-cTnT (ng/l) ¹	1.52 (1.26 - 1.83)	<0.001	1.51 (1.26 - 1.82)	<0.001
NT-proBNP >300pg/ml	4.09 (1.23 - 13.59)	0.021	2.95 (0.92 - 9.52)	0.070
NT-proBNP (pg/ml) ¹	1.26 (1.01 - 1.57)	0.043	1.10 (0.88 - 1.37)	0.386
PESI score ²	1.02 (0.87 - 1.20)	0.781	0.88 (0.69 - 1.14)	0.335
RIETE score ³	1.55 (1.19 - 2.03)	0.001	1.56 (1.20 - 2.04)	0.001
24 months				
hs-cTnT >14ng/l	2.25 (1.32 - 3.86)	0.003	1.87 (1.05 - 3.34)	0.034

hs-cTnT (ng/l) ¹	1.34 (1.14 - 1.58)	<0.001	1.31 (1.10 - 1.55)	0.002
NT-proBNP >300pg/ml	1.77 (1.01 - 3.10)	0.046	1.40 (0.77 - 2.54)	0.266
NT-proBNP (pg/ml) ¹	1.10 (0.94 - 1.28)	0.228	1.01 (0.87 - 1.19)	0.864
PESI score ²	1.03 (0.92 - 1.14)	0.638	0.95 (0.83 - 1.10)	0.486
RIETE score ³	1.30 (1.07 - 1.57)	0.007	1.32 (1.09 - 1.60)	0.004

1 ¹Biomarkers were log-transformed and used continuous. Effects (SHRs) are expressed per one log-unit increase.
 2 ² Effects (SHRs) are expressed per 10 score points increase.
 3 ³ Effects (SHRs) are expressed per score point increase.
 4 *adjusted for RIETE score and periods of anticoagulation as a time-varying covariate. The RIETE score itself
 5 was only adjusted for anticoagulation.
 6

7 Kaplan-Meier curves showed that patients with either hs-cTnT or NT-proBNP values above
 8 the pre-specified cut-off had a significantly higher cumulative incidence of clinically relevant
 9 bleeding up to 24 months than patients with values below the cut-off (37% vs 23% for NT-
 10 proBNP and 41% vs 20% for hs-cTnT, Fig. 2). Regarding major bleeding, only NT-proBNP
 11 values above the pre-specified cut-off had a significantly higher cumulative incidence of
 12 events compared to values below the cut-off (Fig. S3 - supplementary data).

13 **Fig 2. Cumulative incidence of clinically relevant bleeding by level of hs-cTnT (left**
 14 **panel) and NT-proBNP (right panel).** High versus low levels are based on pre-specified cut-
 15 offs (>14 ng/l for hs-cTnT and >300 pg/ml for NT-proBNP).



16
 17 Table 6 summarizes specificity, sensitivity, and predictive values for each cardiac biomarker,
 18 PESI and RIETE score regarding clinically relevant bleeding over time. Both hs-cTnT and
 19 NT-proBNP tend to have a higher negative predictive value (NPV) than RIETE score at any
 20 time point considered. At the pre-specified cut-offs for NT-proBNP (300 pg/ml) and hs-cTnT

1 (14 ng/L), NPVs were 97.3% (95% CI: 90.5 – 99.2) and 96.9% (95% CI: 91.4 – 99.0),
 2 respectively, up to 1 month and remained over 79.5% (95% CI: 68.8 – 87.1) and 81.6% (95%
 3 CI: 72.8 – 88.1), respectively, during the 24 months follow-up period. RIETE score showed
 4 slightly lower NPV values ranging between 93.5% (95% CI: 89.1 – 96.1) up to 1 month and
 5 74.4% (95% CI: 67.9 – 79.9) up to 24 months. Values for major bleeding showed similar
 6 trends (Table S4 - supplementary data).

7 **Table 6. Evolution of sensitivity, specificity, and predictive values over time with**
 8 **clinically relevant bleeding.**

	Sensitivity (95% CI)	Specificity (95% CI)	PPV¹ (95% CI)	NPV² (95% CI)
1 month				
hs-cTnT >14ng/l	85.0 (64.0-94.8)	45.2 (38.7-52.0)	12.9 (8.2-19.7)	96.9 (91.4-99.0)
NT-proBNP >300pg/ml	90.0 (69.9-97.2)	33.8 (27.8-40.4)	11.5 (7.4-17.4)	97.3 (90.5-99.2)
PESI score > 85	60.0 (38.7-78.1)	34.3 (28.2-40.9)	8.0 (4.6-13.5)	90.0 (81.5-94.8)
RIETE score > 4	35.0 (18.1-56.7)	88.6 (83.6-92.2)	22.6 (11.4-39.8)	93.5 (89.1-96.1)
3 months				
hs-cTnT >14ng/l	82.1 (64.4-92.1)	46.0 (39.3-52.9)	17.4 (11.9-24.8)	94.9 (88.6-97.8)
NT-proBNP >300pg/ml	89.3 (72.8-96.3)	34.7 (28.4-41.4)	15.9 (11.0-22.5)	95.9 (88.6-98.6)
PESI score > 85	60.7 (42.4-76.4)	34.2 (28.0-40.9)	11.3 (7.2-17.4)	86.3 (77.0-92.1)
RIETE score > 4	32.1 (17.9-50.7)	89.1 (84.1-92.7)	29.0 (16.1-46.6)	90.5 (85.6-93.8)
24 months				
hs-cTnT >14ng/l	71.9 (59.9-81.4)	48.2 (40.7-55.7)	34.8 (27.3-43.3)	81.6 (72.8-88.1)
NT-proBNP >300pg/ml	76.6 (64.9-85.3)	34.9 (28.1-42.5)	31.2 (24.5-38.8)	79.5 (68.8-87.1)
PESI score > 85	64.1 (51.8-74.7)	34.3 (27.5-41.8)	27.3 (20.8-35.0)	71.3 (60.5-80.0)
RIETE score > 4	20.3 (12.3-31.7)	89.2 (83.5-93.0)	41.9 (26.4-59.2)	74.4 (67.9-79.9)

9 ¹PPV: positive predictive value
 10 ²NPV: negative predictive value

11

12 **Discussion**

13 The major finding of this study is that, among both cardiac biomarkers, only hs-cTnT is found
 14 to be an independent predictor of clinically relevant bleeding susceptible to provide
 15 incremental discriminatory power when added to the RIETE score for bleeding risk prediction
 16 in patients anticoagulated for non-high risk PE. On the contrary, hs-cTnT C-statistics is not

1 substantially modified after addition of the RIETE score. Even though C-statistics
2 comparisons between cardiac biomarkers and RIETE score should be considered exploratory
3 at the present time in PE, these hypothesis-generating results are very similar to what has been
4 shown in the ARISTOTLE trial for hs-cTnT. Indeed, in this study testing the efficacy and
5 safety of apixaban in preventing ischemic stroke in more than 14800 patients with atrial
6 fibrillation (AF), hs-cTnT levels upon admission were found to be significant predictors of
7 subsequent major bleeding. Moreover, hs-cTnT levels improved the C-statistics of the
8 established CHA2DS2VASc score (based on the following items: congestive heart failure,
9 hypertension, 75 years of age and older, diabetes mellitus, previous stroke or transient
10 ischemic attack, vascular disease, 65 to 74 years of age, gender) from 0.591 to 0.629 ($p <$
11 0.0001) regarding the risk of major bleeding (30). Although NT-proBNP levels also improved
12 risk stratification beyond the CHA2DS2VASc risk score, they did not predict subsequent
13 major bleeding risk (31). If both NT-proBNP and hs-cTnT were shown to be appealing
14 candidates for risk stratification in PE (6–12), the current results lend weight to the possibility
15 that hs-cTnT could be the best to capture bleeding propensity upon anticoagulation. In
16 addition, despite being non-significant, C-statistics differences observed between hs-cTnT and
17 the RIETE score ($\Delta=0.10$) is still of a magnitude order that could be perceived as substantial
18 (32). Regarding major bleeding assessment, our results show the same trends with a few
19 exceptions, notably at 24 months of follow-up where RIETE score C-statistics is found to be
20 superior to hs-cTnT. On the other hand, RIETE score is found to be superior to NT-proBNP at
21 any time. Of note, PESI score is not shown to be associated with endpoints in this study. This
22 is not surprising since it has not been developed to predict hemorrhagic complications.
23 The pathophysiological reasons underlying bleeding risk prediction differences between hs-
24 cTnT and NT-proBNP are still poorly understood and are most likely multifactorial. Indeed,
25 aside myocardial necrosis and pressure overload, hs-cTn levels are known to be markedly

1 influenced by age, myocardial apoptosis and fibrosis, and cardiomyocytes turn-over (33).
2 Because cTn (mostly cTnI so far) have been shown to act as anti-angiogenic factors
3 susceptible to disrupt endothelial integrity (18–21), we cannot exclude the fact that hs-cTnT
4 elevations could also reflect the individual bleeding propensity. Even without a complete
5 understanding of the underlying mechanisms associating hs-cTnT with the hemorrhagic risk,
6 hs-cTnT level below 14 ng/L shows an elevated (96.9%) negative predictive value (NPV) for
7 a subsequent haemorrhagic event in PE and this test is available in most routine laboratories.
8 Whether hs-cTnT could represent an attractive candidate to influence the selection of non-
9 massive PE patients susceptible to benefit from a more aggressive treatment than standard
10 anticoagulation alone remains an open question. Being at the opposite of most risk
11 stratification concepts elaborated so far in non-massive PE, such hypothesis warrants further
12 investigations, especially regarding the definition of an optimal cut-off to be used for such
13 purpose.

14 Despite not being optimal for bleeding risk assessment in a rule-in strategy, hs-cTnT values
15 below 14 ng/l show a higher NPV than RIETE score at any time for clinically relevant
16 bleeding with value of 96.9% (95% CI: 91.4-99.0) versus 93.5% (95% CI: 89.1-96.1) at 1
17 month, respectively. In general, hs-cTnT and NT-proBNP NPVs are similar. In contrast, both
18 hs-cTnT and NT-proBNP display, at the pre-specified cut-off values, positive predictive
19 values that were not suitable, at least for the elderly, to identify patients with high risk for
20 bleeding.

21 This study has several limitations. First, the number of events was limited. Although we
22 observed significant associations with the primary endpoint when predictors were used
23 continuous, these associations failed to reach significance when considered as dichotomous in
24 adjusted analyses. Furthermore, the same trend was observed for the secondary endpoint
25 indicating that some of the negative findings values reported here are likely to be ascribed to a

1 power issue. Therefore, knowing whether the pre-specified cut-off for biomarkers used in
2 acute coronary syndrome is adequate for bleeding risk stratification has to be answered.
3 Another limitation resides in the fact that we did not measure the Growth Differentiation
4 Factor 15 (GDF-15), known to have strong CV prognostic values in different clinical settings
5 including PE (34,35), as well as to be a strong predictor of major bleeding in patient
6 anticoagulated for AF (36). These findings led to the validation of a biomarker-based score
7 entitled ABC (age, biomarkers, clinical history)-bleeding risk score in AF patients receiving
8 oral anticoagulant therapy where GDF-15 was one of the most contributing factors (37).
9 Therefore, the question whether GDF-15 would be more strongly associated with major
10 bleeding risk in PE than hs-cTnT certainly remains of interest. Another important limitation
11 of this study resides in the fact that due to study design, we did not include PE patients
12 requiring thrombolysis. Therefore, our results cannot be extrapolated to thrombolysed
13 patients.
14 Due to a power issue associated with a low number of primary endpoint events in chronic
15 kidney failure and cancer patients, such confounding factors cannot be excluded as well as the
16 consequences of different anticoagulant therapy on the occurrence of bleeding.
17 Finally, the validity of the present results in PE patients that are younger than 65 years-old has
18 to be established.

19

20 **Conclusion**

21 This hypothesis-generating study suggests that hs-cTnT has the highest discriminative
22 accuracy among tested cardiac biomarkers and the RIETE score for predicting clinically
23 relevant bleeding. Moreover, given their relatively high negative predictive values for
24 hemorrhagic complications, knowing whether cardiac biomarkers assessment would improve

1 the risk/benefit ratio of thrombolysis in NMPE with radiological signs of right ventricular
2 dysfunction remains to be demonstrated.

4 **Author Contributions statement**

5 Conceived and designed the experiments: DA MR HB MM EG NV. Performed the
6 experiments: NV OG. Analyzed the data: AL NV. Wrote the paper: AS NV MM AL OG EG
7 HB DA MR.

9 **Funding and Conflict of interest statement**

10 This cohort study was supported by the Swiss National Science Foundation (Grant no.
11 33CSO-122659/139470: <http://p3.snf.ch/project-139470>). Reagents costs were partly
12 supported by Roche (Switzerland), and Thermo Scientific (BRAHMS AG,
13 Hennigsdorf/Berlin, Germany) which were not involved in data analyses or results
14 interpretation. The funders had no role in study design, data collection and analysis, decision
15 to publish, or preparation of the manuscript.

16 The authors have no other conflict of interest to disclose.

18 **References**

- 19 1. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al.
20 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
21 Eur Heart J. 2014 Nov 14;35(43):3033–69, 3069a–3069k.
- 22 2. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment
23 of pulmonary embolism with dalteparin. Thromb Haemost. 2000 Feb;83(2):209–11.

- 1 3. Beer JH, Burger M, Gretener S, Bernard-Bagattini S, Bounameaux H. Outpatient
2 treatment of pulmonary embolism is feasible and safe in a substantial proportion of
3 patients. *J Thromb Haemost JTH*. 2003 Jan;1(1):186–7.
- 4 4. Aujesky D, Roy P-M, Verschuren F, Righini M, Osterwalder J, Egloff M, et al. Outpatient
5 versus inpatient treatment for patients with acute pulmonary embolism: an international,
6 open-label, randomised, non-inferiority trial. *Lancet Lond Engl*. 2011 Jul
7 2;378(9785):41–8.
- 8 5. Zwierzina D, Limacher A, Méan M, Righini M, Jaeger K, Beer H-J, et al. Prospective
9 comparison of clinical prognostic scores in elder patients with a pulmonary embolism. *J*
10 *Thromb Haemost JTH*. 2012 Nov;10(11):2270–6.
- 11 6. Coutance G, Le Page O, Lo T, Hamon M. Prognostic value of brain natriuretic peptide in
12 acute pulmonary embolism. *Crit Care*. 2008;12(4):R109.
- 13 7. Vuilleumier N, Le Gal G, Verschuren F, Perrier A, Bounameaux H, Turck N, et al.
14 Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a
15 multicenter prospective study. *J Thromb Haemost JTH*. 2009 Mar;7(3):391–8.
- 16 8. Lankeit M, Friesen D, Aschoff J, Dellas C, Hasenfuss G, Katus H, et al. Highly sensitive
17 troponin T assay in normotensive patients with acute pulmonary embolism. *Eur Heart J*.
18 2010 Aug;31(15):1836–44.
- 19 9. Lankeit M, Jiménez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P, et al.
20 Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary
21 Embolism Severity Index in hemodynamically stable patients with acute pulmonary
22 embolism: a prospective validation study. *Circulation*. 2011 Dec 13;124(24):2716–24.
- 23 10. Agterof MJ, Schutgens REG, Snijder RJ, Epping G, Peltenburg HG, Posthuma EFM, et
24 al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-
25 proBNP level. *J Thromb Haemost JTH*. 2010 Jun;8(6):1235–41.
- 26 11. Vuilleumier N, Limacher A, Méan M, Choffat J, Lescuyer P, Bounameaux H, et al.
27 Cardiac biomarkers and clinical scores for risk stratification in elderly patients with non-
28 high-risk pulmonary embolism. *J Intern Med*. 2015 Jun;277(6):707–16.
- 29 12. Vuilleumier N, Simona A, Méan M, Limacher A, Lescuyer P, Gerstel E, et al.
30 Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly
31 Patients with Non-Massive Pulmonary Embolism. *PloS One*. 2016;11(5):e0155973.
- 32 13. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al.
33 Fibrinolysis for patients with intermediate-risk pulmonary embolism. *N Engl J Med*. 2014
34 Apr 10;370(15):1402–11.
- 35 14. Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, et
36 al. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk
37 Pulmonary Embolism. *J Am Coll Cardiol*. 2017 Mar 28;69(12):1536–44.
- 38 15. Qian J-Y, Haruno A, Asada Y, Nishida T, Saito Y, Matsuda T, et al. Local expression of
39 C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced

- 1 thrombosis, and prevents neointima formation through enhanced nitric oxide production
2 in rabbit injured carotid arteries. *Circ Res*. 2002 Nov 29;91(11):1063–9.
- 3 16. Yoshizumi M, Tsuji H, Nishimura H, Masuda H, Kunieda Y, Kawano H, et al. Natriuretic
4 peptides regulate the expression of tissue factor and PAI-1 in endothelial cells. *Thromb*
5 *Haemost*. 1999 Nov;82(5):1497–503.
- 6 17. Yoshizumi M, Tsuji H, Nishimura H, Kasahara T, Sugano T, Masuda H, et al. Atrial
7 natriuretic peptide inhibits the expression of tissue factor and plasminogen activator
8 inhibitor 1 induced by angiotensin II in cultured rat aortic endothelial cells. *Thromb*
9 *Haemost*. 1998 Mar;79(3):631–4.
- 10 18. Xie Q, Yao S, Chen X, Xu L, Peng W, Zhang L, et al. A polypeptide from shark troponin
11 I can inhibit angiogenesis and tumor growth. *Mol Biol Rep*. 2012 Feb;39(2):1493–501.
- 12 19. Schmidt K, Hoffend J, Altmann A, Kiessling F, Strauss L, Koczan D, et al. Troponin I
13 overexpression inhibits tumor growth, perfusion, and vascularization of morris hepatoma.
14 *J Nucl Med Off Publ Soc Nucl Med*. 2006 Sep;47(9):1506–14.
- 15 20. Kern BE, Balcom JH, Antoniu BA, Warshaw AL, Fernández-del Castillo C. Troponin I
16 peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo
17 effects on human endothelial cells and on pancreatic cancer. *J Gastrointest Surg Off J Soc*
18 *Surg Aliment Tract*. 2003 Dec;7(8):961–8; discussion 969.
- 19 21. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, et al.
20 Troponin I is present in human cartilage and inhibits angiogenesis. *Proc Natl Acad Sci U*
21 *S A*. 1999 Mar 16;96(6):2645–50.
- 22 22. Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL, et al.
23 Predictive variables for major bleeding events in patients presenting with documented
24 acute venous thromboembolism. Findings from the RIETE Registry. *Thromb Haemost*.
25 2008 Jul;100(1):26–31.
- 26 23. Guijarro R, Montes J, Sanromán C, Monreal M, RIETE Investigators. Venous
27 thromboembolism in Spain. Comparison between an administrative database and the
28 RIETE registry. *Eur J Intern Med*. 2008 Oct;19(6):443–6.
- 29 24. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. Derivation and
30 Validation of a Prognostic Model for Pulmonary Embolism. *Am J Respir Crit Care Med*.
31 2005 Oct 15;172(8):1041–6.
- 32 25. Méan M, Righini M, Jaeger K, Beer H-J, Frauchiger B, Osterwalder J, et al. The Swiss
33 cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and
34 methodology. *J Thromb Thrombolysis*. 2013 Nov;36(4):475–83.
- 35 26. Kämpfen P, Méan M, Limacher A, Righini M, Jaeger K, Beer H-J, et al. Risk of falls and
36 bleeding in elderly patients with acute venous thromboembolism. *J Intern Med*. 2014
37 Oct;276(4):378–86.
- 38 27. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and
39 Standardization Committee of the International Society on Thrombosis and Haemostasis.

- 1 Definition of major bleeding in clinical investigations of antithrombotic medicinal
2 products in non-surgical patients. *J Thromb Haemost JTH*. 2005 Apr;3(4):692–4.
- 3 28. Méan M, Aujesky D, Lämmle B, Gerschheimer C, Trelle S, Angelillo-Scherrer A. Design
4 and establishment of a biobank in a multicenter prospective cohort study of elderly
5 patients with venous thromboembolism (SWITCO65+). *J Thromb Thrombolysis*. 2013
6 Nov;36(4):484–91.
- 7 29. Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk AU
8 - Fine, Jason P. *J Am Stat Assoc*. 1999 Jun 1;94(446):496–509.
- 9 30. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, et al. High-
10 sensitivity troponin T and risk stratification in patients with atrial fibrillation during
11 treatment with apixaban or warfarin. *J Am Coll Cardiol*. 2014 Jan 7;63(1):52–61.
- 12 31. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-
13 terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial
14 fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke
15 in Subjects With Atrial Fibrillation). *J Am Coll Cardiol*. 2013 Jun 4;61(22):2274–84.
- 16 32. Pencina MJ, D'Agostino RB, Massaro JM. Understanding increments in model
17 performance metrics. *Lifetime Data Anal*. 2013 Apr;19(2):202–18.
- 18 33. Twerenbold R, Boeddinghaus J, Nestelberger T, Wildi K, Rubini Gimenez M,
19 Badertscher P, et al. Clinical Use of High-Sensitivity Cardiac Troponin in Patients With
20 Suspected Myocardial Infarction. *J Am Coll Cardiol*. 2017 Aug 22;70(8):996–1012.
- 21 34. Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in
22 Cardiovascular Disease. *Clin Chem*. 2017 Jan;63(1):140–51.
- 23 35. Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, et al. Growth differentiation
24 factor-15 for prognostic assessment of patients with acute pulmonary embolism. *Am J*
25 *Respir Crit Care Med*. 2008 May 1;177(9):1018–25.
- 26 36. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al.
27 Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk
28 assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in
29 Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
30 *Circulation*. 2014 Nov 18;130(21):1847–58.
- 31 37. Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. The
32 novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for
33 patients with atrial fibrillation: a derivation and validation study. *Lancet Lond Engl*. 2016
34 Jun 4;387(10035):2302–11.

35

36 **Corresponding author**

37 Aurélien Simona, Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and
38 Faculty of Medicine, Geneva, Switzerland. E-mail : Aurelien.Simona@hcuge.ch

1 **Alternative proof reader**

2 Nicolas Vuilleumier, E-mail : Nicolas.Vuilleumier@hcuge.ch